Skip to main content
Erschienen in: Pathology & Oncology Research 2/2009

01.06.2009 | Original Paper

Correliation Between Osteopontin Protein Expression and Histological Grade of Astrocytomas

verfasst von: H Toy, O Yavas, O Eren, M Genc, C Yavas

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Osteopontin is a ligand for the integrin proteins, which are cell surface receptors that mediate the physical and functional interactions between a cell and the extracellular matrix. The expression of osteopontin is reportedly increased in a number of transformed cell lines and tumor tissues. Furthermore, increased expression of osteopontin results in some infiltrative features of tumors. The aim of the study is to demonstrate that expression of osteopontin in human astrocytomas correlates with histological tumor grade. The expression of osteopontin in human astrocytomas was determined with immunohistochemistry. Median osteopontin expression levels were 1%, 7.5%, 60%, and 50% in grade I, II, III, and IV tumors, respectively. Osteopontin staining was significantly higher in high grade (grade III–IV) than low grade (grade I–II) tumors. These findings indicate that osteopontin immunoreactivity in human astrocytomas may correlate with the grade of a tumor.
Literatur
1.
Zurück zum Zitat Denhardt DT, Noda M (1998) Osteopontin expression and function: role in bone modelling. J Cell Biochem Supply (30–31):92–102CrossRef Denhardt DT, Noda M (1998) Osteopontin expression and function: role in bone modelling. J Cell Biochem Supply (30–31):92–102CrossRef
2.
3.
Zurück zum Zitat Ritting SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br Journal Cancer 90:1877–1881CrossRef Ritting SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br Journal Cancer 90:1877–1881CrossRef
4.
Zurück zum Zitat Weber GF, Ashkar S, Glimcher MJ, Cantor H (1996) Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 26, 271(5248):509–12CrossRef Weber GF, Ashkar S, Glimcher MJ, Cantor H (1996) Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 26, 271(5248):509–12CrossRef
5.
Zurück zum Zitat Senger DR, Wirth DF, Hynes RO (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16:885–893PubMedCrossRef Senger DR, Wirth DF, Hynes RO (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16:885–893PubMedCrossRef
6.
Zurück zum Zitat Brown Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol 145(3):610–23 Brown Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol 145(3):610–23
7.
Zurück zum Zitat Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1(5):621–32PubMedCrossRef Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1(5):621–32PubMedCrossRef
8.
Zurück zum Zitat Tucker MA, Chang PL, Prince CW, Gillespie GY, Mapstone TB (1998) TPA-mediated regulation of osteopontin in human malignant glioma cells. Anticancer Res 18(2A):807–12PubMed Tucker MA, Chang PL, Prince CW, Gillespie GY, Mapstone TB (1998) TPA-mediated regulation of osteopontin in human malignant glioma cells. Anticancer Res 18(2A):807–12PubMed
9.
Zurück zum Zitat Chambers AF, Wilson SM, Kerkvliet N, O, Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancer. Lung Cancer 15(3):311–23PubMedCrossRef Chambers AF, Wilson SM, Kerkvliet N, O, Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancer. Lung Cancer 15(3):311–23PubMedCrossRef
10.
Zurück zum Zitat Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10(1 Pt 1):184–90PubMedCrossRef Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10(1 Pt 1):184–90PubMedCrossRef
11.
Zurück zum Zitat Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62(12):3417–27PubMed Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62(12):3417–27PubMed
12.
Zurück zum Zitat Anita Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG (2004) Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 36(6):1046–69PubMedCrossRef Anita Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG (2004) Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 36(6):1046–69PubMedCrossRef
13.
Zurück zum Zitat Roland Goldbrunner RH, Bernstein JJ, Tonn JC (1998) ECM-mediated glioma cell invasion. Microsc Res Tech 43(3):250–7CrossRef Roland Goldbrunner RH, Bernstein JJ, Tonn JC (1998) ECM-mediated glioma cell invasion. Microsc Res Tech 43(3):250–7CrossRef
14.
Zurück zum Zitat Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y (1995) Expression of osteopontin in human glioma. Its correlation with the malignancy.. Lab Invest 72(1):55–63 Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y (1995) Expression of osteopontin in human glioma. Its correlation with the malignancy.. Lab Invest 72(1):55–63
15.
Zurück zum Zitat Jang T, Savarese T, Low HP, Kim S, Vogel H, Lapointe D, Duong T, Litofsky NS, Weimann JM, Ross AH, Recht L (2006) Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea. Am J Pathol 168(5):1676–85PubMedCrossRef Jang T, Savarese T, Low HP, Kim S, Vogel H, Lapointe D, Duong T, Litofsky NS, Weimann JM, Ross AH, Recht L (2006) Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea. Am J Pathol 168(5):1676–85PubMedCrossRef
16.
Zurück zum Zitat Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I, Martin PM, Ouafik L, Figarella-Branger D (2005) Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene 12:1–9 Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I, Martin PM, Ouafik L, Figarella-Branger D (2005) Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene 12:1–9
17.
Zurück zum Zitat Ding Q, Stewart J Jr, Prince CW, Chang PL, Trikha M, Han X, Grammer JR, Gladson CL (2002) Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 62(18):5336–43PubMed Ding Q, Stewart J Jr, Prince CW, Chang PL, Trikha M, Han X, Grammer JR, Gladson CL (2002) Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 62(18):5336–43PubMed
18.
Zurück zum Zitat Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, Flentje M, Roosen K, Vordermark D (2007) Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 83(3):398–405PubMedCrossRef Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, Flentje M, Roosen K, Vordermark D (2007) Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 83(3):398–405PubMedCrossRef
Metadaten
Titel
Correliation Between Osteopontin Protein Expression and Histological Grade of Astrocytomas
verfasst von
H Toy
O Yavas
O Eren
M Genc
C Yavas
Publikationsdatum
01.06.2009
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2009
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9130-0

Weitere Artikel der Ausgabe 2/2009

Pathology & Oncology Research 2/2009 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.